Economic Evaluation of Vortioxetine in the Treatment of Major Depressive Disorder of Patients Who Have Failed Treatment with Selective Serotonin Reuptake Inhibitors
Author(s)
ABSTRACT WITHDRAWN
Objective: The aim of this study is to determine the cost-effectiveness of vortioxetine versus duloxetine and venlafaxine in adults with major depressive disorder (MDD) who have failed treatment with selective serotonin reuptake inhibitors (SSRIs) from the perspective of the National Health System (NHS) of Mexico. Methods: We conducted a systematic review (SR) in PubMed, Cochrane, LILACS and Imbiomed databases to evaluate the efficacy and safety of vortioxetine compared to duloxetine and venlafaxine. Afterward, we performed a complete cost-effectiveness economic evaluation using a decision tree model with the information obtained in the SR. The outcome measure was the percentage of patients who did not drop out due to adverse events (Baldwin et al., 2016). The time horizon was eight weeks, in which we consider the use of resources associated with the interventions evaluated and the adverse events presented. The direct medical costs were considered and obtained from NHS purchasing portals in Mexico. Additionally, a budget impact analysis was conducted to calculate the financial impact of the inclusion of vortioxetine as a treatment option in the NHS for adult patients with MDD who have failed treatment with SSRIs. Results: Vortioxetine has an tolerability measure of 93.4% and an average cost per patient of $ 1,937.98. Duloxetine and venlafaxine have an tolerability measure of 91.2% and 85.8% and an average cost per patient of $1,961.80 MXN and $2,279.25 MXN, respectively. When calculating the Incremental Cost-Effectiveness Ratio, vortioxetine represents a "dominant" choice compared to duloxetine and venlafaxine. In a period of 5 years, the inclusion of vortioxetine would imply an average saving of $163,566 MxN. Conclusions: When considering the percentage of patients who did not drop out due to adverse events, vortioxetine represents a "dominant", efficient and savings option for the Mexican NHS.
Conference/Value in Health Info
2022-05, ISPOR 2022, Washington, DC, USA
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Code
EE90
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas